1. Home
  2. PNNT vs AVXL Comparison

PNNT vs AVXL Comparison

Compare PNNT & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PennantPark Investment Corporation

PNNT

PennantPark Investment Corporation

HOLD

Current Price

$3.47

Market Cap

251.4M

Sector

Finance

ML Signal

HOLD

Logo Anavex Life Sciences Corp.

AVXL

Anavex Life Sciences Corp.

HOLD

Current Price

$2.52

Market Cap

237.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PNNT
AVXL
Founded
2007
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
251.4M
237.2M
IPO Year
2007
2013

Fundamental Metrics

Financial Performance
Metric
PNNT
AVXL
Price
$3.47
$2.52
Analyst Decision
Hold
Strong Buy
Analyst Count
5
3
Target Price
$5.75
$22.00
AVG Volume (30 Days)
834.4K
1.3M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
20.87%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.30
$2.41
52 Week High
$7.53
$13.99

Technical Indicators

Market Signals
Indicator
PNNT
AVXL
Relative Strength Index (RSI) 41.89 42.55
Support Level $3.30 $2.41
Resistance Level $3.59 $2.80
Average True Range (ATR) 0.10 0.16
MACD 0.03 0.02
Stochastic Oscillator 58.62 26.67

Price Performance

Historical Comparison
PNNT
AVXL

About PNNT PennantPark Investment Corporation

Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

Share on Social Networks: